Abstract
Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials
Highlights
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function and worsening dyspnoea [1]
We assessed the cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline using pooled data from the TOMORROW and INPULSIS trials
Most patients (90%) in these trials were defined as having higher cardiovascular risk at baseline, of which 78% had one or more cardiovascular risk factors but no history of atherosclerotic cardiovascular disease (CVD)
Summary
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease characterised by decline in lung function and worsening dyspnoea [1]. Cardiovascular diseases (CVDs) represent common comorbidities in patients with IPF [2,3,4,5,6]. Cardiovascular conditions associated with IPF include ischaemic heart disease (IHD), cerebrovascular disease and systemic arterial hypertension [2, 4]. Cardiovascular risk is a continuum and is influenced by a number of risk factors. Guidelines for prevention of CVD issued by the European Society of Cardiology recommend an assessment of total cardiovascular risk in apparently healthy adults aged >40 years or those with relevant risk factors such as smoking, hypertension, cholesterol levels and diabetes [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
